Guggenheim Maintains Buy on Prometheus Biosciences, Raises Price Target to $225
Guggenheim analyst Yatin Suneja maintains Prometheus Biosciences (NASDAQ:RXDX) with a Buy and raises the price target from $185 to $225.
Goldman Sachs Maintains Buy on Prometheus Biosciences, Raises Price Target to $144
Goldman Sachs analyst Chris Shibutani maintains Prometheus Biosciences (NASDAQ:RXDX) with a Buy and raises the price target from $117 to $144.
Bulls In A Bear Market: These 10 Stocks Clocked Gains In Excess Of 100% In 2022
2022 would go down as one of the worst years for the financial markets. The sell-off has been all-pervasive, with stocks, bonds and cryptos all selling off indiscriminately. Even as high-fliers like Apple Inc.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.
Why Prometheus Biosciences Stock Is Falling
Prometheus Biosciences Inc (NASDAQ: RXDX) shares are trading lower by 6.01% to $110.16 going into the close of Friday's session after the company priced a public upsized $500 million offering.
Reported Late Thursday, Prometheus Biosciences Announces Pricing Of Public Upsized $500M Offering Of 4,545,455 Shares Of Common Stock At A Price Of $110/Share
Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion
Lowe’s To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
Goldman Sachs raised Lowe’s Companies, Inc. (NYSE:LOW) price target from $241 to $246. . Goldman Sachs analyst Kate…
Credit Suisse Maintains Outperform on Prometheus Biosciences, Raises Price Target to $142
Credit Suisse analyst Tiago Fauth maintains Prometheus Biosciences (NASDAQ:RXDX) with a Outperform and raises the price target from $59 to $142.
BTIG Maintains Buy on Prometheus Biosciences, Raises Price Target to $181
BTIG analyst Julian Harrison maintains Prometheus Biosciences (NASDAQ:RXDX) with a Buy and raises the price target from $74 to $181.